NIH Begins Clinical Trial for Coronavirus Vaccine

On March 16, NIH issued a news release detailing the start of a Phase 1 clinical trial on a COVID-19 vaccine taking place in Seattle, Washington. The vaccine was developed by NIAID scientists in collaboration with Moderna, Inc. and will be tested on 45 health adults between ages 18 and 45. NIAID Director Anthony Fauci, MD, noted “Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority. This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

Click here to read the full news release: "NIH clinical trial of investigational vaccine for COVID-19 begins."